Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Allergan Boosts Outlook

By Pharmaceutical Processing | October 9, 2014

NEW YORK (AP) — Allergan, which has been fending off buyout offers from Valeant Pharmaceuticals, boosted its earnings outlook for the year and current quarter.

The Botox maker said Wednesday that new products, regulatory approval and its rising market share is helping boost results.

The company now expects third-quarter earnings of between $1.76 per share and $1.78 per share, up from its previous forecast between $1.44 per share and $1.47 per share. It expects revenue to rise 17 percent from the same quarter a year ago, to about $1.79 billion. Analysts expected earnings of $1.47 per share and revenue of $1.74 billion, according to FactSet.

For the full year, it now expects earnings between $6.20 per share and $6.25 per share, up from its previous forecast between $5.74 per share and $5.80 per share. Revenue is expected to rise 14 or 15 percent from the year before, to between about $7.17 billion and $7.24 billion. Analysts expected earnings of $5.80 per share and revenue of $7.09 billion.

Allergan also provided a long-term outlook, saying it expects earnings of $8.60 per share next year and $10.25 per share in 2016. Both were above analyst expectations.

The company has rejected several offers from Canadian drugmaker Valeant, with the most recent being a $53 billion bid in June.

Shares of the Allergan, based in Irving, California, rose $1.54 to $192.04 in morning trading.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE